ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...

ImmunityBio stock jumps after strong trial updates in bladder cancer and lymphoma, with enrollment ahead of schedule and FDA ...

Early data of Waldenström’s non-Hodgkin lymphoma patients enrolled in a trial testing Immunitybio Inc.’s off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK), ...

GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein prevalent across breast, lung, ovarian, pancreatic, prostate, bladder, and ...

RoboSense (02498 HKEX), a pioneering AI-driven robotics technology company, has been ranked No.1 in the 2025 3D LiDAR Sales ...

Extendicare Inc. ("Extendicare" or the "Company") announced today that it plans to release its financial results for the fourth quarter of 2025 after market close on Thursday, February 26, 2026. A ...

ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials. It also ...

A new cancer therapy wakes up immune cells inside tumors and turns them against cancer.